文献速递脑血管病认知障碍与痴呆

强化血压治疗与亚临床脑梗死:SPRINT(收缩压干预试验)的二次分析

Intensive Blood Pressure Treatment and Subclinical Brain Infarcts: A Secondary Analysis of SPRINT (Systolic Pressure Intervention Trial).
PubMed 文献 · Ann Neurol · 2024-02-16

该研究为SPRINT试验的二次分析,纳入≥50岁、收缩压130-180mmHg、心血管风险升高但无临床卒中、痴呆或糖尿病的患者,随机接受强化(<120mmHg)或标准(<140mmHg)收缩压治疗。基线667例中75例(11%)存在亚临床脑梗死;中位随访3.9年时,457例中12例出现新发亚临床脑梗死(强化组5例,标准组7例),8例发生临床卒中(每组4例)。基线亚临床脑梗死与新发亚临床脑梗死或卒中相关(sHR=3.90),且基线有亚临床脑梗死者强化治疗可降低复发风险(sHR=0.050)。

要点

  • 基线亚临床脑梗死患病率为11%(75/667)。
  • 基线亚临床脑梗死增加新发亚临床脑梗死或卒中风险(sHR=3.90)。
  • 基线有亚临床脑梗死者,强化治疗降低复发风险(sHR=0.050)。

核心结论

  • 新发脑缺血事件不常见,但强化治疗减轻了基线有亚临床脑梗死参与者的风险升高,表明存在亚临床脑梗死时初级预防的收缩压目标仍然适用。

研究设计与样本

  • SPRINT(收缩压干预试验)的二次分析,参与者≥50岁、收缩压130-180mmHg、心血管风险升高但无已知临床卒中、痴呆或糖尿病,随机接受强化(<120mmHg)或标准(<140mmHg)收缩压治疗。
  • 基线与随访脑磁共振图像用于判读亚临床脑梗死,并评估轻度认知障碍或 probable dementia(可能痴呆)的发生。

主要发现

  • 基线667例中,75例(11%)存在亚临床脑梗死。
  • 中位随访3.9年时,457例中12例出现新发亚临床脑梗死(强化组5例,标准组7例),8例发生临床卒中(每组4例)。
  • 基线亚临床脑梗死与新发亚临床脑梗死或卒中相关(sHR=3.90;95%CI 1.49至10.24;p=0.006),治疗分组无此关联。
  • 基线有亚临床脑梗死的参与者中,强化治疗降低复发亚临床脑梗死或卒中风险(sHR=0.050;95%CI 0.0031至0.79;p=0.033)。
  • 基线亚临床脑梗死增加随访期间轻度认知障碍或可能痴呆风险(sHR=2.38;95%CI 1.23至4.61;p=0.010)。

关键数值与推荐

  • 强化收缩压目标为<120mmHg,标准收缩压目标为<140mmHg。
  • 基线亚临床脑梗死与新发亚临床脑梗死或卒中关联的sHR=3.90(95%CI 1.49至10.24;p=0.006)。
  • 基线有亚临床脑梗死时强化治疗与复发亚临床脑梗死或卒中关联的sHR=0.050(95%CI 0.0031至0.79;p=0.033)。
  • 基线亚临床脑梗死与轻度认知障碍或可能痴呆关联的sHR=2.38(95%CI 1.23至4.61;p=0.010)。

临床怎么用

  • 原文结论指出,存在亚临床脑梗死时初级预防的收缩压目标仍然适用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Subclinical brain infarcts (SBI) increase the risk for stroke and dementia, but whether they should be considered equivalent to symptomatic stroke when determining blood pressure targets remains unclear. We tested whether intensive systolic blood pressure (SBP) treatment reduced the risk of new SBI or stroke and determined the association between SBI and cognitive impairment. METHODS: In this secondary analysis of SPRINT (Systolic Pressure Intervention Trial), participants ≥50 years old, with SBP 130-180mmHg and elevated cardiovascular risk but without known clinical stroke, dementia, or diabetes, were randomized to intensive (<120mmHg) or standard (<140mmHg) SBP treatment. Brain magnetic resonance images collected at baseline and follow-up were read for SBI. The occurrence of mild cognitive impairment (MCI) or probable dementia (PD) was evaluated. RESULTS: For 667 participants at baseline, SBI were identified in 75 (11%). At median 3.9 years follow-up, 12 of 457 had new SBI on magnetic resonance imaging (5 intensive, 7 standard), whereas 8 had clinical stroke (4 per group). Baseline SBI (subhazard ratio [sHR] = 3.90; 95% CI 1.49 to 10.24; p = 0.006), but not treatment group, was associated with new SBI or stroke. For participants with baseline SBI, intensive treatment reduced their risk for recurrent SBI or stroke (sHR = 0.050; 95% CI 0.0031 to 0.79; p = 0.033). Baseline SBI also increased risk for MCI or PD during follow-up (sHR = 2.38; 95% CI 1.23 to 4.61; p = 0.010). INTERPRETATION: New cerebral ischemic events were infrequent, but intensive treatment mitigated the increased risk for participants with baseline SBI, indicating primary prevention SBP goals are still appropriate when SBI are present. ANN NEUROL 2024;95:866-875.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Kern KC, Nasrallah IM, Bryan RN, et al. Intensive Blood Pressure Treatment and Subclinical Brain Infarcts: A Secondary Analysis of SPRINT (Systolic Pressure Intervention Trial). Ann Neurol. 2024. PMID: 38362733. doi:10.1002/ana.26892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。